StreetInsider.com News Articles

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

Mon, 21 Sep 2026 12:00:00 -0400

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET.

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

Mon, 21 Sep 2026 12:00:00 -0400

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at

Cullinan Oncology Inc. (CGEM) PT Raised to $40 at BTIG

Mon, 14 Sep 2026 12:45:18 -0400

BTIG analyst Julian Harrison raised the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $40.00 (from $39.00) while maintaining a Buy rating.

The analyst comments "CGEM presented positive Phase 3 REZILIENT3 data during a Presidential Symposium at the IASLC 2026 WCLC, demonstrating a statistically significant improvement in PFS for zipalertinib + chemo vs chemo alone in 1L EGFR exon20ins NSCLC. The combination reduced the risk of disease progression by 50% (HR=0.50; p=0.00015) and improved mPFS to 14.5 months vs 8.5 months for chemo alone, while also improving objective response rate (65.0% vs. 40.3%) and extending median duration of response (14.2

Cullinan Oncology Inc. (CGEM) PT Raised to $40 at BTIG

Mon, 14 Sep 2026 12:45:18 -0400

BTIG analyst Julian Harrison raised the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $40.00 (from $39.00) while maintaining a Buy rating.

Stifel Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Mon, 14 Sep 2026 11:05:59 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $28.00 price target on Cullinan Oncology Inc. (NASDAQ: CGEM).

The analyst comments "We reiterate our Buy Rating on CGEM following presentation of the REZILIENT3 Ph3 data of Zipalertinib in 1L EGFR ex20mut NSCLC. On the primary endpoint PFS, Zipalertinib+chemo demonstrated a 14.5- vs. 8.5-month benefit (p=0.00015) at the interim with early trends on overall survival. Bottom line, these data look competitive/better on a cross-trial basis vs. amivantamab (efficacy and safety) and could support meaningful share accrual over time. CGEM has a 50/50 profit share with Taiho and is also eligible for $130MM

TD Cowen Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)

Mon, 14 Sep 2026 11:05:30 -0400

TD Cowen analyst Phil Nadeau reiterated a Buy rating on Cullinan Oncology Inc. (NASDAQ: CGEM).

The analyst comments "We currently model peak sales of $225MM based on 25% penetrance of the 4.5K U.S. population and 12 months average duration, based mainly on use in 2L. The REZILIENT3 results suggest there is much potential upside to both penetration and average duration relative to our initial estimates, implying peak sales potential of $1B. Zipa's NDA is currently under review for approval in the 2L setting with a Feb. 27 PDUFA. While regulatory filing is ultimately controlled by Taiho, management notes that the REZILIENT3

Cullinan Therapeutics to host investor event on Phase 3 lung cancer trial

Mon, 14 Sep 2026 07:00:27 -0400

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced it will host a virtual event for analysts and institutional investors to discuss interim analysis results from its Phase 3 REZILIENT3 trial, which evaluated zipalertinib in combination with chemotherapy.

The data were presented at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer, in a Presidential Symposium session.

The virtual event is scheduled for 8:00 a.m. ET on Sept. 14, 2026. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer.

The Cambridge, Mass.-based company said a live webcast and subsequent replay will

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Mon, 14 Sep 2026 07:00:00 -0400

Company to host a virtual event today at 8:00 a.m. ET

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s (IASLC)

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Mon, 14 Sep 2026 07:00:00 -0400

Company to host a virtual event today at 8:00 a.m. ET

Zipalertinib combo shows 6-month PFS gain in lung cancer trial

Sun, 13 Sep 2026 19:15:22 -0400

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (Nasdaq: CGEM) announced results from the Phase 3 REZILIENT3 trial showing that zipalertinib combined with platinum-based chemotherapy produced a statistically significant improvement in progression-free survival (PFS) for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).

The data, presented at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer in Seoul, South Korea, showed a median PFS of 14.5 months for the combination arm versus 8.5 months for chemotherapy alone, a difference of 6.0 months (HR=0.50; 95% CI, 0.34-0.73; P=0.00015).

The trial enrolled 279 patients with

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Sun, 13 Sep 2026 19:15:00 -0400

Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion mutation NSCLC at a planned interim analysis

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC).

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Sun, 13 Sep 2026 19:15:00 -0400

Cullinan Therapeutics to host investor event after Phase 3 lung cancer trial data

Thu, 10 Sep 2026 13:00:13 -0400

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will host a virtual event for analysts and institutional investors on September 14, 2026, at 8:00 a.m. ET to discuss results from a planned interim analysis of its Phase 3 REZILIENT3 trial.

The trial evaluated zipalertinib combined with chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC). According to the company, the trial met its primary endpoint of progression-free survival at the planned interim analysis.

The data are scheduled to be presented in Presidential Symposium 2 on September 13, 2026, at the International Association for the Study of

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Thu, 10 Sep 2026 13:00:00 -0400

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026

Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Thu, 10 Sep 2026 13:00:00 -0400

Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET

Form 4 Cullinan Therapeutics, For: Sep 08 Filed by: Michaelson Jennifer

Thu, 10 Sep 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260910/27046343.html

TD Cowen Assumes Cullinan Oncology Inc. (CGEM) at Buy

Sat, 22 Aug 2026 07:55:05 -0400

TD Cowen analyst Phil Nadeau assumes coverage on Cullinan Oncology Inc. (NASDAQ: CGEM) with a Buy rating.

For an analyst ratings summary and ratings history on Cullinan Oncology Inc. click here. For more ratings news on Cullinan Oncology Inc. click here.

Shares of Cullinan Oncology Inc. closed at $21.68 yesterday.

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that interim analysis results from the Phase 3 REZILIENT3 trial have been selected for presentation at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer, scheduled for September 12-15, 2026, in Seoul, South Korea.

The data will be presented during Presidential Symposium 2 on September 14, 2026. According to the companies, the trial met its primary endpoint of progression-free survival in the first-line treatment of patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib trial data to be presented at IASLC lung cancer conference

Wed, 19 Aug 2026 12:03:15 -0400

The REZILIENT3 trial is a multicenter, randomized, controlled, open-label

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Wed, 19 Aug 2026 12:03:00 -0400

Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLC

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been selected for presentation in the Presidential Symposium 2 at the International Association for the Study of Lung Cancer's (IASLC) 2026 World Conference on Lung Cancer (WCLC), to be held September 12-15, 2026, in

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Wed, 19 Aug 2026 12:03:00 -0400

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Wed, 19 Aug 2026 12:03:00 -0400

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Wed, 19 Aug 2026 12:03:00 -0400